Glaukos (NYSE:GKOS) Price Target Raised to $226.00

Posted by Brian Himes on Nov 1st, 2026

Glaukos (NYSE:GKOS – Free Report) had its price objective upped by Wells Fargo & Company from $178.00 to $226.00 in a research report released on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the medical instruments supplier’s stock.

Several other research analysts also recently weighed in on GKOS. Needham & Company LLC lifted their target price on shares of Glaukos from $201.00 to $251.00 and gave the stock a “buy” rating in a research report on Thursday. BTIG Research upped their price target on shares of Glaukos from $205.00 to $234.00 and gave the company a “buy” rating in a research report on Thursday. Truist Financial raised their price objective on shares of Glaukos from $215.00 to $255.00 and gave the stock a “buy” rating in a research note on Thursday. UBS Group assumed coverage on shares of Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $216.71.

View Our Latest Stock Report on GKOS

Glaukos Trading Down 2.3%

NYSE:GKOS opened at $236.92 on Thursday. The company has a quick ratio of 4.46, a current ratio of 4.57 and a debt-to-equity ratio of 0.09. Glaukos has a 1-year low of $80.90 and a 1-year high of $248.75. The firm has a market capitalization of $14.03 billion, a price-to-earnings ratio of -80.58 and a beta of 0.69. The stock has a fifty day simple moving average of $173.30 and a 200 day simple moving average of $141.14.

Glaukos (NYSE:GKOS – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. The firm had revenue of $211.03 million for the quarter, compared to analysts’ expectations of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. Glaukos’s revenue was up 58.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.16) EPS. Sell-side analysts forecast that Glaukos will post 0.15 earnings per share for the current year.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert Kliman sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total transaction of $475,000.00. Following the completion of the sale, the director owned 37,406 shares of the company’s stock, valued at $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 60,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 82,500 shares of company stock worth $14,862,000 in the last 90 days. 5.90% of the stock is owned by insiders.

Institutional Trading of Glaukos

Several institutional investors have recently modified their holdings of the company. Allworth Financial LP bought a new position in Glaukos during the second quarter worth about $28,000. CoreCap Advisors LLC bought a new stake in shares of Glaukos in the 3rd quarter valued at approximately $33,000. Fortitude Family Office LLC bought a new stake in shares of Glaukos in the 3rd quarter valued at approximately $36,000. Provenance Wealth Advisors LLC acquired a new position in shares of Glaukos in the 3rd quarter worth approximately $44,000. Finally, IFP Advisors Inc raised its stake in Glaukos by 523.4% during the second quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 246 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

Positive Sentiment: Glaukos reported third-quarter revenue of approximately $211 million, up 58% year over year and well above the $168 million analyst consensus. Earnings were $0.47 per share versus expectations for a $0.10–$0.12 loss and a $0.16 loss in the prior-year quarter. Glaukos Q3 earnings and revenues surpass estimates
Positive Sentiment: Management raised fiscal 2026 revenue guidance to $775 million–$785 million, substantially above the roughly $691.5 million consensus estimate. It also set a preliminary fiscal 2027 sales target of $1 billion, versus Wall Street expectations of about $849 million, reinforcing the growth story. Glaukos sets $1 billion 2027 sales goal
Positive Sentiment: Analyst sentiment improved following the results. Zacks Research upgraded GKOS from “hold” to “strong buy,” while Needham raised its price target to $251 and JPMorgan lifted its target to $240, maintaining an “overweight” rating.
Neutral Sentiment: Other firms also raised their targets, including Wells Fargo to $226, BTIG to $234 and Stifel to $225. However, each remains below the recent trading level, suggesting analysts are becoming more constructive while still seeing limited near-term upside at the current valuation.
Negative Sentiment: The headline profit included factors that may not fully reflect recurring operating earnings. Glaukos continues to report a negative net margin, and commentary noted that underlying profitability is thinner than adjusted figures suggest. With a price-to-earnings ratio based on losses and the stock near its 52-week high, expectations and valuation remain elevated.

About Glaukos

(Get Free Report)

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.